Earnings History Data for Royalty Pharma plc (RPRX) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Royalty Pharma plc
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15-02-2024 | PM | RPRX | Royalty Pharma plc | 17,510 | 1.15 | 1.03 | 1.56 | Royalty Pharma reports Q4 results [2/15/2024 7:38 AM] |
30.02 | 0.93 (3.18%) |
30.12 | 1.03 (3.54%) |
25.92 - 38.51 | 3,179,414 | 3,350,000 | 2,457 | ||
| 08-11-2023 | PM | RPRX | Royalty Pharma plc | 16,720 | 0.79 | 0.81 | 0.73 | Royalty Pharma reports Q3 results [11/8/2023 8:48 AM] |
27.62 | 0.07 (0.25%) |
27.62 | 0.0 (0.00%) |
25.92 - 44.47 | 2,583,794 | 1,900,000 | 22,136 | ||
| 08-08-2023 | PM | RPRX | Royalty Pharma plc | 18,580 | 0.85 | 0.83 | 0.79 | Royalty Pharma reports Q2 results [8/8/2023 7:09 AM] |
30.55 | -0.27 (-0.86%) |
31.90 | 1.08 (3.50%) |
29.20 - 44.66 | 2,275,833 | 1,830,000 | 6,850 | ||
| 09-05-2023 | PM | 7:00 AM ET (May 9) |
RPRX | Royalty Pharma plc | 15,560 | 1.60 | 1.31 | 0.61 | Royalty Pharma reports Q1 results [5/9/2023 7:07 AM] |
33.98 | -1.55 (-4.35%) |
0.0 | 0.0 (0.00%) |
32.68 - 44.66 | 2,141,138 | 1,660,000 | 0 | |
| 15-02-2023 | PM | 7:00 AM ET (Feb 15) |
RPRX | Royalty Pharma plc | 16,810 | 1.56 | 1.52 | 0.80 | Royalty Pharma reports Q4 results [2/15/2023 7:04 AM] |
37.72 | -0.08 (-0.21%) |
38.00 | 0.20 (0.53%) |
36.15 - 44.75 | 1,442,642 | 1,920,000 | 2,414 | |
| 08-11-2022 | PM | 7:00 AM ET (Nov 8) |
RPRX | Royalty Pharma plc | 18,560 | 0.73 | 0.71 | 0.73 | Royalty Pharma reports Q3 results; raises FY22 guidance [11/8/2022 7:03 AM] |
42.70 | 0.34 (0.79%) |
41.00 | -1.37 (-3.23%) |
36.15 - 44.75 | 1,250,977 | 1,530,000 | 826 | |
| 04-08-2022 | PM | 7:00 AM ET (Aug 4) |
RPRX | Royalty Pharma plc | 18,820 | 0.79 | 0.78 | 0.71 | Royalty Pharma Non-GAAP EPS of -$2.68, revenue of $36.5M [8/4/2022 6:45 AM] |
42.45 | -0.40 (-0.93%) |
43.00 | 0.15 (0.35%) |
34.86 - 44.75 | 958,149 | 2,050,000 | 1,399 | |
| 05-05-2022 | PM | 7:00 AM ET (May 5) |
RPRX | Royalty Pharma plc | 18,510 | 0.61 | 0.72 | 0.67 | Royalty Pharma reports Q1 results [5/5/2022 7:15 AM] |
40.72 | -2.48 (-5.74%) |
43.50 | 0.30 (0.69%) |
34.86 - 47.10 | 2,608,871 | 2,260,000 | 2,439 | |
| 15-02-2022 | PM | 7:00 AM ET (Feb 15) |
RPRX | Royalty Pharma plc | 17,120 | 0.80 | 0.79 | 0.28 | Royalty Pharma reports Q4 results [2/15/2022 7:05 AM] |
40.30 | 1.19 (3.04%) |
39.04 | -0.07 (-0.18%) |
34.86 - 48.79 | 1,978,909 | 1,590,000 | 1,713 | |
| 10-11-2021 | PM | 7:00 AM ET (Nov 10) |
RPRX | Royalty Pharma plc | 16,880 | 0.73 | 0.69 | 0.48 | Royalty Pharma beats on revenue [11/10/2021 7:24 AM] |
41.60 | 2.00 (5.05%) |
40.49 | 0.89 (2.25%) |
34.86 - 53.23 | 4,088,477 | 2,010,000 | 1,433 | |
| 11-08-2021 | PM | 7:00 AM ET (Aug 11) |
RPRX | Royalty Pharma plc | 22,330 | 0.71 | 0.70 | 0.73 | Royalty Pharma beats on revenue [8/11/2021 7:05 AM] |
36.69 | 0.26 (0.71%) |
36.69 | 0.0 (0.00%) |
34.80 - 53.23 | 4,262,350 | 3,370,000 | 5,298 | |
| 11-05-2021 | PM | 7:00 AM ET (May 11) |
RPRX | Royalty Pharma plc | 24,870 | 0.67 | 0.65 | 0.00 | Royalty Pharma beats on revenue [5/11/2021 7:05 AM] |
41.68 | 0.19 (0.46%) |
41.68 | 0.0 (0.00%) |
34.80 - 56.50 | 3,037,567 | 1,420,000 | 4,567 | |
|
||||||||||||||||||
| 17-02-2021 | PM | 7:00 AM ET (Feb 17) |
RPRX | Royalty Pharma plc | 30,000 | 0.28 | 0.70 | 0.00 | Royalty Pharma beats on revenue [2/17/2021 7:10 AM] |
47.35 | -0.16 (-0.34%) |
49.00 | 1.49 (3.14%) |
34.80 - 56.50 | 1,754,586 | 1,305,510 | 15,120 | |
| 10-11-2020 | AH | 7:00 AM ET (Nov 11) |
RPRX | Royalty Pharma Plc | 24,430 | 0.48 | 0.59 | 0.00 | Royalty Pharma beats on revenue [11/10/2020 5:50 PM] |
40.30 | -0.30 (-0.74%) |
41.90 | 1.30 (3.20%) |
34.80 - 56.50 | 5,098,972 | 1,618,070 | 8,952 | |
|
|
||||||||||||||||||
| 10-11-2020 | AH | 7:00 AM ET (Nov 11) |
RPRX | Royalty Pharma plc | 24,870 | 0.48 | 0.59 | 0.00 | Royalty Pharma beats on revenue [11/10/2020 5:50 PM] |
40.30 | -0.30 (-0.74%) |
41.90 | 1.30 (3.20%) |
34.80 - 56.50 | 5,098,972 | 1,618,070 | 8,952 | |
|
|
||||||||||||||||||
| 12-08-2020 | PM | 8:45 AM ET (Aug 12) |
RPRX | Royalty Pharma plc | 27,780 | 0.73 | 0.61 | 0.00 | Royalty Pharma beats on revenue [8/12/2020 7:05 AM] |
44.96 | -0.81 (-1.77%) |
46.40 | 0.63 (1.38%) |
39.90 - 56.50 | 1,016,930 | 959,253 | 11,134 | |
|
|
||||||||||||||||||